Jim Heath used to be a director for Stryker who appears to be advising us in the commercialisation of the FRG technology in the medical sector! We are in a pool of high profile groups and individuals! A high end small cap short term, a mid cap high growth stock medium term and a large cap stock in the making! We’re projected 2.7b revenue and 770m NPAT by 2025 as per beer and co’s evaluation.
Ann: Half Yearly Report and Accounts, page-25
Add PO3 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.078M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| PO3 (ASX) Chart |
Day chart unavailable
